Skip to main content

Elinzanetant Efficacious, Well-Tolerated for Vasomotor Symptoms

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 27, 2024.

via HealthDay

TUESDAY, Aug. 27, 2024 -- For menopausal vasomotor symptoms (VMS), elinzanetant is efficacious and well-tolerated, according to a study published online Aug. 22 in the Journal of the American Medical Association.

JoAnn V. Pinkerton, M.D., from the University of Virginia Health in Charlottesville, and colleagues examined the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of moderate-to-severe menopausal VMS in two randomized, double-blind, phase 3 trials (OASIS 1 and 2), including postmenopausal participants aged 40 to 65 years. Eligible participants were randomly assigned to elinzanetant 120 mg for 26 weeks (199 and 200 in OASIS 1 and 2, respectively) or matching placebo for 12 weeks followed by elinzanetant 120 mg for 14 weeks (197 and 200 in OASIS 1 and 2, respectively).

The researchers found a significant reduction in VMS frequency with elinzanetant at week 4 (−3.3 and −3.0 in OASIS 1 and 2, respectively) and week 12 (−3.2 and −3.2 in OASIS 1 and 2, respectively). In addition, the severity of VMS was improved with elinzanetant at week 4 (−0.3 and −0.2 in OASIS 1 and 2, respectively) and week 12 (−0.4 and −0.3 in OASIS 1 and 2, respectively). Improvement in sleep disturbances and menopause-related quality of life was seen with elinzanetant at week 12, and the safety profile was favorable.

"Elinzanetant has the potential to provide a well-tolerated and efficacious nonhormonal treatment option to address the unmet health needs of many menopausal individuals with moderate-to-severe VMS," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Bayer, which manufactures elinzanetant and funded the OASIS 1 and 2 trials.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Regular Sexual Activity Linked to Fewer Genitourinary-Related Symptoms in Menopause

THURSDAY, July 3, 2025 -- Regular sexual activity is associated with a lower prevalence of genitourinary syndrome of menopause (GSM)-related symptoms, according to a study...

Moderate-to-Severe Asthma Up for Female Permanent Night Shift Workers

THURSDAY, June 26, 2025 -- Female permanent night shift workers have higher odds of moderate-to-severe asthma than female day workers, but this relationship is not seen in men...

Plant-Based Diet Tied to Weight Loss, Fewer Hot Flashes in Postmenopausal Women

THURSDAY, June 5, 2025 -- A plant-based diet rich in soy, regardless of the level of processing, may benefit both hot flash and weight management in postmenopausal women...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.